RxDoctor Payments Data

Craig Gluckman, MD

Gastroenterology · West Hills, CANPI 1881942506

Payments from drug & device makers

$1,369in general payments, 2019–2025

Across 15 payments — averaging $91.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Redhill Biopharma Inc.$223
  • Janssen Scientific Affairs, LLC$217
  • Regeneron$125
  • AbbVie$125
  • E.r. Squibb & Sons, L.L.C.$124
  • Novo Nordisk$121
  • plus $434 from 7 others

What the payments were for

  • Food & beverage$1,33898%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,369 in reported general payments places this provider in the 40th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$277,920
Medicare patients
835
Services billed
2,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab23$183,966
LinzessLinaclotide73$72,440
MotegrityPrucalopride Succinate31$25,029
Mesalamine32$16,987
ZenpepLipase/Protease/Amylase12$16,605
ClenpiqSod Picosulf/Mag Ox/Citric Ac71$12,239
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates85$5,297
Omeprazole271$4,491
Pantoprazole Sodium163$3,168
Dexlansoprazole DrDexlansoprazole11$2,807
Budesonide EcBudesonide11$2,800
Famotidine149$2,258
Sucralfate28$1,324
Esomeprazole Magnesium18$1,150
Ondansetron OdtOndansetron41$696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$125$72,44073 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →